Fp357effect of Raas Blockade in Adults With Diabetes Mellitus and Advanced Chronic Kidney Disease Not on Dialysis: A Systematic Review and Meta-Analysis

Covic, Adrian; Sutter, Johan De; Drechsler, Christiane; Goldsmith, David; Soler, María José; Tomson, Charles; Wiȩcek, Andrzej; Donciu, Mihaela-Dora; Bolignano, Davide; Biesen, Wim Van; Nistor, Ionuţ

doi:10.1093/ndt/gfv175.39

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a systematic review and meta-analysis study of 9 clinical trials with 9,797 participants, the effect of RAASis on all-cause mortality and CV mortality in DM patients with advanced CKD was not significantly different compared with control groups (placebo or other antihypertensive drugs). 27 However, patients treated with ACEis experienced a mild 10% reduction in the risk of developing nonfatal CVEs and a 19% risk reduction in the need for renal replacement and doubling of the SCr. 27 These results indicate a small but beneficial effect of ACEis on the survival of patients with more advanced CKD.…”

Section: Diabetic Patientsmentioning

confidence: 99%

“…27 However, patients treated with ACEis experienced a mild 10% reduction in the risk of developing nonfatal CVEs and a 19% risk reduction in the need for renal replacement and doubling of the SCr. 27 These results indicate a small but beneficial effect of ACEis on the survival of patients with more advanced CKD. Combination therapy with ACEis and ARBs has no beneficial effect on survival or CV symptoms in patients with diabetes nephropathy.…”

Section: Diabetic Patientsmentioning

confidence: 99%

See 1 more Smart Citation

The Ongoing Management of Hyperkalaemia in Chronic Kidney Disease Patients: Cases for Clinical Decisions

Ledesma¹

2015

EMJ Nephrol

View full text Add to dashboard Cite

This educational symposium provided an insight into the most current clinical evidence of the efficacy and safety of renin—angiotensin—aldosterone system inhibitors (RAASis) for patients with chronic kidney disease (CKD). The programme provided an opportunity to discuss ways to optimise and maintain RAASis in this population by introducing CKD patient cases and the dilemmas of their clinical presentation, and novel treatment options, including benefits, harms, and potential consequences. Prof David C. Wheeler introduced the debate about the use of RAASis and the associated risk of hyperkalaemia in CKD patients. Prof Francesco Locatelli discussed the management of blood pressure (BP) in CKD and reviewed the most current guidelines for the prevention of hyperkalaemia in this population. Prof Adrian Covic presented the controversies around the use of RAASis in specific group populations. Survival, cardiovascular events (CVEs), and progression of CKD were the main points of his presentation. Finally, Prof David C. Wheeler discussed the latest research on novel therapies for the management of hyperkalaemia.

show abstract

Section: Diabetic Patientsmentioning

confidence: 99%

Section: Diabetic Patientsmentioning

confidence: 99%